- Home
- FENC vs EPIX Comparison
FENC vs EPIX Comparison
Compare FENC & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- EPIX
- Stock Information
- Founded
- FENC 1996
- EPIX 2009
- Country
- FENC United States
- EPIX Canada
- Employees
- FENC N/A
- EPIX N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- FENC Health Care
- EPIX Health Care
- Exchange
- FENC Nasdaq
- EPIX Nasdaq
- Market Cap
- FENC 181.7M
- EPIX 209.4M
- IPO Year
- FENC 2001
- EPIX N/A
- Fundamental
- Price
- FENC $3.99
- EPIX $1.72
- Analyst Decision
- FENC Strong Buy
- EPIX Hold
- Analyst Count
- FENC 2
- EPIX 4
- Target Price
- FENC $14.00
- EPIX $9.50
- AVG Volume (30 Days)
- FENC 116.0K
- EPIX 2.4M
- Earning Date
- FENC 11-07-2024
- EPIX 12-10-2024
- Dividend Yield
- FENC N/A
- EPIX N/A
- EPS Growth
- FENC N/A
- EPIX N/A
- EPS
- FENC N/A
- EPIX N/A
- Revenue
- FENC $49,348,000.00
- EPIX N/A
- Revenue This Year
- FENC $116.50
- EPIX N/A
- Revenue Next Year
- FENC $17.49
- EPIX N/A
- P/E Ratio
- FENC N/A
- EPIX N/A
- Revenue Growth
- FENC 278.09
- EPIX N/A
- 52 Week Low
- FENC $3.97
- EPIX $1.40
- 52 Week High
- FENC $11.92
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- FENC 38.47
- EPIX 23.15
- Support Level
- FENC $3.99
- EPIX $1.75
- Resistance Level
- FENC $4.57
- EPIX $1.89
- Average True Range (ATR)
- FENC 0.31
- EPIX 0.19
- MACD
- FENC -0.02
- EPIX -0.10
- Stochastic Oscillator
- FENC 2.33
- EPIX 7.36
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.